Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 513
- Registration Number
- NCT05699408
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 117
- Registration Number
- NCT05685420
Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT05661591
- Locations
- 🇨🇳
Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT05607693
- Locations
- 🇨🇳
Cancer Hospital of Tianjin, Tianjin, Tianjin, China
Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05592262
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05560360
- Locations
- 🇨🇳
The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China
A Non-intervention Fiberoptic Bronchoscopy Study of Remazolam Toluene Sulfonate for Injection Under General Anesthesia and Fiberoptic Bronchoscopy
- Conditions
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT05549791
Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT05533463
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, ShangHai, Shanghai, China
A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT05522439
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Effect of SHR8058 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 312
- Registration Number
- NCT05515471
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, Beijing, China
© Copyright 2024. All Rights Reserved by MedPath